Mundipharma has signed an agreement with Moberg Pharma to commercialize Emtrix® - its leading product for nail fungus and nail psoriasis - in the Middle East and Africa under Mundipharma’s BETADINE® consumer healthcare brand.
Fungal infections can cause onychomycosis, which can result in thickening, splitting, roughening and discoloration of both toenails and fingernails. It is estimated that about 2% to 13.8% of adults are affected by onychomycosis, and the prevalence increases with age reaching 25–30% in the elderly. Infections can be painful, impact a patient’s self-image and are associated with increased risk of secondary infection. Left untreated, it can cause serious limitations to mobility.
Applied to deformed nails resulting from fungal infection, such as onychomycosis, as well as psoriasis that occurs in nails, Emtrix® improves the appearance of damaged nails by reducing discoloration, normalizing thickness, and hydrating brittle nails.
Mundipharma CEO, Raman Singh, said: “This agreement is another example of Mundipharma expanding its operations to provide better healthcare options for more patients. Many more people will now be able to access one of the leading products for these common and uncomfortable conditions.
“This addition complements Mundipharma’s existing portfolio of BETADINE®^ treatments, including infection control products, which have been trusted by healthcare professionals and consumers around the world for over 50 years.”
“We look forward to developing our relationship with Mundipharma and making Emtrix® available in new regions as we expand our footprint in growing markets”, says Peter Wolpert, Moberg Pharma’s CEO.